Global pharmaceutical fine chemicals market is expected to grow during the forecast period owing to the increasing demand for outsourcing. Pharmaceutical and biotechnology companies are the major end-users of the fine chemicals market. Increasing amount of research work done by these companies lead to rising demand for fine chemicals. The drug patents are getting expired and the global generic market is growing. In this case, the fine chemicals market is driven by rising demand of generic drug molecules. Technological advancements in the production procedures, shifting interests of producers towards newer biotechnological methods, and introduction of innovative products are the factors making pharmaceutical fine chemicals market attractive to new entrants with tremendous future scope of innovation. The growth however is expected to boost owing to the strategies devised by the pharmaceutical companies with mergers and acquisitions with the local fine chemicals manufacturers. Use of fine chemicals for other purposes such as in agriculture, food is expected to fuel the fine chemicals market during the forecast period. Moreover, the market may be slowed down with growing competitors and reduction in the prices of the fine chemicals.
To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/pharmaceutical-fine-chemicals-market
Based on the therapeutic uses, pharmaceutical fine chemicals market is segmented into cardiovascular, neurological, oncological, infectious diseases, metabolic system, diabetes, respiratory, gastrointestinal, mucoskeletal and others. Cardiovascular is one of the largest markets in 2013 owing to the rising prevalence of diseases such as cardiac arrest, heart attack and atherosclerosis. Diabetes is another major segment of this market owing to the increasing number of cases and unavailability of the permanent cure. Use of fine chemicals in vitamin supplements has great scope for market growth with increasing demand for vitamin supplements. On the basis of type of drugs, the market is segmented into proprietary and non proprietary drugs. Nearly 85% of the market is held by proprietary drugs. However, non proprietary market is expected to grow owing to the expected patent expiration of some chemicals. On the basis of the type of chemicals, the market can also be segmented into small molecules and big molecules. The big molecules segment currently holds the largest market share owing to the usage of chemicals such as di-peptides in cardiovascular diseases. Other than pharmaceuticals; applications of peptides in vaccines and diagnostics is expected to push the market growth in the segment. Developments in neurological therapeutics and demand for vitamin supplements are the drivers for the market growth in small molecules segment.
Geographically, pharmaceutical fine chemicals market is segmented as North America, Europe, Asia Pacific, MEA and Latin America. North America has been leading the market in the past few years owing to the attempts of big pharmaceutical companies for production restructuring and to shift the focus on research and development to stabilize the competition. The dominance of the region is expected to continue during the forecast period owing to increasing patent expiration and growing generics market. Asia Pacific is expected to be the fastest growing region in the pharmaceutical fine chemicals market. The growth is fostered mainly due to the rising demand of fine chemicals from pharmaceutical companies in the developed countries for their R&D activities. The numbers of competitors are increasing which tend to reduce the prices of the fine chemicals. The demand is high in companies implementing good manufacturing practices (cGMP) in the region. India only has over 70 companies complying cGMP. Easy availability of raw materials, developing economy and favorable drug policies by government are expected to boost the pharmaceutical fine chemicals market in the region.
Major players in the pharmaceutical fine chemicals market are AstraZeneca, GlaxoSmithKlein, Abbot, Amgen, Roche, Merck and co., Sanofi-Aventis, Bristol-Myers Squibb Otsuka, Johnson and Johnson, and Novartis. Fine chemicals producers serving the pharmaceutical industry are increasing their production capacities by adopting newer technologies and offering new chemical entities as intermediates and reaction mixtures.
To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/pharmaceutical-fine-chemicals-market
Based on the therapeutic uses, pharmaceutical fine chemicals market is segmented into cardiovascular, neurological, oncological, infectious diseases, metabolic system, diabetes, respiratory, gastrointestinal, mucoskeletal and others. Cardiovascular is one of the largest markets in 2013 owing to the rising prevalence of diseases such as cardiac arrest, heart attack and atherosclerosis. Diabetes is another major segment of this market owing to the increasing number of cases and unavailability of the permanent cure. Use of fine chemicals in vitamin supplements has great scope for market growth with increasing demand for vitamin supplements. On the basis of type of drugs, the market is segmented into proprietary and non proprietary drugs. Nearly 85% of the market is held by proprietary drugs. However, non proprietary market is expected to grow owing to the expected patent expiration of some chemicals. On the basis of the type of chemicals, the market can also be segmented into small molecules and big molecules. The big molecules segment currently holds the largest market share owing to the usage of chemicals such as di-peptides in cardiovascular diseases. Other than pharmaceuticals; applications of peptides in vaccines and diagnostics is expected to push the market growth in the segment. Developments in neurological therapeutics and demand for vitamin supplements are the drivers for the market growth in small molecules segment.
Geographically, pharmaceutical fine chemicals market is segmented as North America, Europe, Asia Pacific, MEA and Latin America. North America has been leading the market in the past few years owing to the attempts of big pharmaceutical companies for production restructuring and to shift the focus on research and development to stabilize the competition. The dominance of the region is expected to continue during the forecast period owing to increasing patent expiration and growing generics market. Asia Pacific is expected to be the fastest growing region in the pharmaceutical fine chemicals market. The growth is fostered mainly due to the rising demand of fine chemicals from pharmaceutical companies in the developed countries for their R&D activities. The numbers of competitors are increasing which tend to reduce the prices of the fine chemicals. The demand is high in companies implementing good manufacturing practices (cGMP) in the region. India only has over 70 companies complying cGMP. Easy availability of raw materials, developing economy and favorable drug policies by government are expected to boost the pharmaceutical fine chemicals market in the region.
Major players in the pharmaceutical fine chemicals market are AstraZeneca, GlaxoSmithKlein, Abbot, Amgen, Roche, Merck and co., Sanofi-Aventis, Bristol-Myers Squibb Otsuka, Johnson and Johnson, and Novartis. Fine chemicals producers serving the pharmaceutical industry are increasing their production capacities by adopting newer technologies and offering new chemical entities as intermediates and reaction mixtures.
Roche and GlaxoSmithKline Pharmaceuticals Limited were the companies implementing strategies related to outsourcing R&D and acquiring products while in the clinical trials. Many companies such as Dishman Pharmaceuticals and Chemicals Ltd. and Aesica Pharmaceuticals have strong pipeline of fine chemicals which is helping them to stay in the competition despite the global crisis. Undergoing developments of the new chemicals in the R&D institutes are the factors affecting the growth of any company in pharmaceutical fine chemicals market.
Get more information of Tunable Laser Market on TOC:
http://www.grandviewresearch.com/industry-analysis/pharmaceutical-fine-chemicals-market/request-toc
About Grand View Research:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: www.grandviewresearch.com
No comments:
Post a Comment